Get Medical Devices news alerts
YOKNEAM, Israel, May 9, 2019 - Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, is proud to announce that its patented MOSES Urology Laser Technology has garnered Lumenis finalist status in the 2019 Medical Design Excellence Awards (MDEA). MOSES, already adopted by hundreds of healthcare facilities worldwide, has demonstrated a variety of clinical advantages and benefits in both Holmium Laser Lithotripsy and Benign Prostatic Hyperplasia (BPH) treatments, including faster procedures, optimized energy delivery, and greater ablation efficiency.
The MDEA program celebrates the "accomplishments of the medical device manufacturers, their suppliers, and the many people behind the scenes — engineers, scientists, designers, and clinicians — who are responsible for the cutting-edge products that are saving lives, improving patient healthcare, and transforming medtech, one innovation at a time." The 2019 MDEA Juror Panel, comprised of practicing doctors, nurses, technicians, industrial designers, engineers, manufacturers, and human factors experts, selected 46 exceptional finalists in nine medical technology product categories. MOSES was chosen as one of the six finalists in the ER and OR Tools, Equipment, and Supplies category. Products and technologies were judged based on patient benefits, business benefits, overall benefit to the healthcare system, design and engineering innovation and function, and user-related innovation.
"We are honored to receive recognition by MDEA for the MOSES Technology, which is redefining the standard of care in lithotripsy and BPH treatment," commented Tzipi Ozer-Armon, CEO of Lumenis. "Innovative technologies like MOSES are the result of Lumenis' heritage of innovation and longevity in the world of medical devices and medical laser technology. MOSES is the manifestation of our continuous collaboration with key opinion leaders as well as with leading teaching and research institutions, who were deeply involved in the development of this groundbreaking technology. On behalf of the entire Lumenis team, we are grateful for finalist status and extend congratulations to all other finalists."